cardiometabolic

Cardiometabolic is a term used to describe the interrelated metabolic and cardiovascular risk factors that together increase the likelihood of cardiovascular disease and metabolic disorders such as type 2 diabetes. The concept emphasizes common pathophysiology, including insulin resistance, obesity, dyslipidemia, hypertension, and inflammation.

Core components often include abdominal or overall obesity, insulin resistance or impaired glucose regulation, dyslipidemia (for example high triglycerides and low HDL cholesterol), elevated blood pressure, and elevated fasting glucose. Inflammation and a prothrombotic state are frequently implicated as well.

Cardiometabolic syndrome refers to the clustering of these risk factors in an individual, conferring markedly higher risk for cardiovascular disease and diabetes. Definitions vary, but most require central adiposity plus two additional factors such as raised triglycerides or low HDL, high blood pressure, or elevated fasting glucose.

Risk factors include genetics, age, sex, and ethnicity, with lifestyle factors such as physical inactivity, obesogenic diet, smoking, and poor sleep contributing substantially. Socioeconomic status and access to healthy foods and care also influence risk.

Assessment generally involves measurements of waist circumference or body mass index, blood pressure, lipid panel, and fasting glucose or HbA1c. Management focuses on lifestyle modification—weight reduction, regular physical activity, and a balanced diet—while pharmacotherapy targets individual components as needed (for example statins, antihypertensives, glucose-lowering agents).

Public health relevance is high due to the association with cardiovascular disease, stroke, and type 2 diabetes. Early identification and integrated prevention strategies that address multiple risk factors are central to reducing cardiometabolic burden at both individual and population levels.